We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial (PRICT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00761423
Recruitment Status : Completed
First Posted : September 29, 2008
Last Update Posted : May 18, 2017
Erasmus Medical Center
Information provided by (Responsible Party):
Zimmer Biomet

Brief Summary:
The study will be a double-blind randomized single-center clinical trial comparing 3 treatment groups with chronic midportion Achilles tendinopathy.

Condition or disease Intervention/treatment Phase
Achilles Tendinopathy Biological: PRP Injection with eccentric exercises Biological: Placebo Injection with eccentric exercises Phase 4

Detailed Description:

Introduction- Overuse injury of the Achilles tendon is a common entity in athletes and older athletes are at an increased risk. When the exact origin of tendon pain is unclear, the term tendinopathy is preferred. Most accepted treatment at this moment is an eccentric exercise programme, according to the Dutch guidelines. However, a recent systematic review on the effectiveness of eccentric exercises to treat lower extremity tendinoses concluded that it is unclear whether eccentric exercises are more effective than other forms of treatment.

Recent studies described new treatment strategies in tendinopathies, such as the use of platelet-rich plasma (PRP). Platelets can participate actively in tissue repair processes and stimulate the release of several growth factors. Recently, it was found that platelet-rich plasma clot releasate stimulates cell proliferation, collagen deposition, and enhances the gene expression of matrix degrading enzymes and endogenous growth factors by human tendon cells in vitro. The only published clinical cohort study in tendon research reported 93% reduction of pain for PRP-treated patients with chronic elbow tendinosis. Also on short term follow-up, the PRP injection was more beneficial than injection with an anaesthetic agent.

Aim- To monitor the potential clinical improvement of chronic midportion Achilles tendinopathy after injection with PRP and to evaluate the recovery process in time using a new Ultrasonographic method (Ultrasonographic Tissue Characterisation).

Hypothesis: The average VISA-A score is higher in the patient group treated with eccentric exercise therapy in combination with a PRP injection in comparison with the group treated with a saline injection in combination with eccentric exercises.

Study population- In total, 54 patients with symptomatic Achilles tendinopathy will be included in the study.

Study design- The study will be a double-blind randomised single-centre clinical trial comparing 2 treatment groups. The researcher, the sports medicine physician and the patients will be blinded to the received therapy.

Therapy- All patients will perform a heavy load eccentric exercise programme, consisting of 180 repetitions daily. The patients will be randomised into 2 treatment groups: ultrasound guided intratendinous saline injection with eccentric exercises and ultrasound guided intratendinous PRP injection with eccentric exercises.

Follow-up- Follow-up (clinically and ultrasonographically) will be at 6, 12, 24 and 52 weeks. At 24 weeks, the researcher will be unblinded after the analysis of the preliminary data. The patients will remain blinded to the therapy until 52 weeks follow-up. At 52 weeks follow-up a second, blinded researcher will evaluate the patients using the primary and secondary outcome measurements.

Outcome measurements- Primary outcome measurement: VISA-A score, a validated instrument to detect the severity of symptoms in patients with Achilles tendinopathy. As secondary outcome measurements subjective patient satisfaction and return to sports will be rated. For the evaluation of tendon repair, Ultrasonographic Tissue Characterization (UTC) and Power Doppler ultrasound (PDU) will be performed. UTC was previously developed in horse tendons and provides quantitative information on tendon fiber alignment and the related ultra-structural integrity of the tendon tissue through a non-invasive approach.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 81 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial
Study Start Date : August 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : August 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tendinitis

Arm Intervention/treatment
Experimental: 1
Combination of eccentric exercises and injection of PRP
Biological: PRP Injection with eccentric exercises
PRP Injection with eccentric exercises

Placebo Comparator: 2
Combination of eccentric exercises and physiological saline injection
Biological: Placebo Injection with eccentric exercises
Placebo Injection with eccentric exercises

Primary Outcome Measures :
  1. VISA-A Score [ Time Frame: 6, 12, 24 and 52 weeks ]

Secondary Outcome Measures :
  1. Ultrasonographic Tissue Characterization [ Time Frame: 6,12, 24 and 52 weeks ]
  2. Complications [ Time Frame: Anytime ]
  3. Power doppler sound [ Time Frame: 6, 12, 24 and 52 weeks ]
  4. Patient satisfaction [ Time Frame: 6, 12, 24 and 52 weeks ]
  5. Return to sport [ Time Frame: 6, 12, 24 and 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Clinical diagnosis "chronic midportion Achilles tendinopathy"
  2. Age 18-70 years

Exclusion criteria

  1. Clinical suspicion of insertional disorders (pain at the site of the insertion of the Achilles tendon on the calcaneum)
  2. Clinical suspicion of an Achilles tendon rupture (Thompson test abnormal and palpabel "gap")
  3. Clinical suspicion of plantar flexor tenosynovitis (posteromedial pain when the toes are plantar flexed against resistance)
  4. Clinical suspicion of n.suralis pathology (sensitive disorder in the area of the sural nerve)
  5. Clinical suspicion of peroneal subluxation (visible luxation of the mm. Peroneï spot in combination with localized pain)
  6. Suspicion of internal disorders: spondylarthropathy, gout, hyperlipidemia, Rheumatoid Arthritis and sarcoidosis.
  7. Condition that prevents the patients from executing an active exercise programme
  8. Patient has already performed eccentric exercises, according to the schedule of Alfredson et al (12 weeks)
  9. Patient has already received an injection of PRP for this injury
  10. Patient does not wish, for whatever reason, to undergo one of the two treatments
  11. Known presence of a pregnancy
  12. Condition of the Achilles tendon caused by medications (arising in relation to moment of intake), such as quinolones and statins

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00761423

Layout table for location information
Erasmus Medical Center
Rotterdam, Netherlands
Sponsors and Collaborators
Zimmer Biomet
Erasmus Medical Center
Layout table for investigator information
Principal Investigator: RJ De Vos, MD Erasmus Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zimmer Biomet
ClinicalTrials.gov Identifier: NCT00761423    
Other Study ID Numbers: BMET NL 02
First Posted: September 29, 2008    Key Record Dates
Last Update Posted: May 18, 2017
Last Verified: May 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Musculoskeletal Diseases
Tendon Injuries
Wounds and Injuries